



LKT Laboratories, Inc.

Lapatinib Ditosylate Monohydrate

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID L0360

CAS No. 388082-78-8

Chemical Name

Synonym

Formula $C_{26}H_{26}ClFN_4O_4S \cdot 2C_7H_8O_3S$

Formula Wt. 925.46

Melting Point 236-259 °C


Purity ≥99%

Solubility Slightly in DMSO

Store Temp 4 °C

Ship Temp Ambient

Description Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
L0360	5 mg	\$47.30
L0360	10 mg	\$68.30
L0360	25 mg	\$89.30
L0360	100 mg	\$210.00

References Janni W, Sarosiek T, Karaszewska B, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. *Breast Cancer Res Treat.* 2014 Jan 9. [Epub ahead of print]. PMID: 24402830.

Kostyal D, Welt RS, Danko J, et al. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. *Med Oncol.* 2012 Sep;29(3):1486-94. PMID: 21769502.

Kim HP, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. *PLoS One.* 2009 Jun 16;4(6):e5933. PMID: 19529774.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.